PIC 060

Drug Profile

PIC 060

Latest Information Update: 28 Mar 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Procept
  • Class Antihyperglycaemics; Antipsoriatics
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Psoriasis; Transplant rejection; Type 1 diabetes mellitus

Most Recent Events

  • 28 Mar 2003 No development reported - Preclinical for Psoriasis in USA (PO)
  • 21 Feb 2000 Procept has merged with Heaven's Door Corporation to form HeavenlyDoor.com
  • 21 Feb 2000 Pacific Pharmaceuticals is now called Procept and has the biotechnology assets of the former Procept
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top